| __timestamp | Alnylam Pharmaceuticals, Inc. | Amicus Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 20717000 |
| Thursday, January 1, 2015 | 60610000 | 47269000 |
| Friday, January 1, 2016 | 89354000 | 71151000 |
| Sunday, January 1, 2017 | 199365000 | 88671000 |
| Monday, January 1, 2018 | 382359000 | 127200000 |
| Tuesday, January 1, 2019 | 479005000 | 169861000 |
| Wednesday, January 1, 2020 | 588420000 | 156407000 |
| Friday, January 1, 2021 | 620639000 | 192710000 |
| Saturday, January 1, 2022 | 770658000 | 213041000 |
| Sunday, January 1, 2023 | 795646000 | 275270000 |
| Monday, January 1, 2024 | 975526000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, understanding spending patterns is crucial. Alnylam Pharmaceuticals and Amicus Therapeutics, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive growth strategy. In contrast, Amicus's expenses increased by approximately 1,200%, indicating a more measured approach.
Alnylam's spending peaked in 2023, with expenses nearly quadrupling since 2018. This rapid increase underscores its commitment to expanding its market presence. Meanwhile, Amicus's expenses, though lower, have steadily climbed, highlighting its focus on sustainable growth. The data reveals a fascinating narrative of strategic financial management in the biotech sector, offering insights into how these companies prioritize their resources to drive innovation and market expansion.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Amicus Therapeutics, Inc. Trends and Insights
Amicus Therapeutics, Inc. or Vericel Corporation: Who Manages SG&A Costs Better?
Amicus Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Amicus Therapeutics, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs Mesoblast Limited
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Travere Therapeutics, Inc.